As of 2024-12-15, the Relative Valuation of Newron Pharmaceuticals SpA (NWRN.SW) is (15.33) CHF. This relative valuation is based on P/E multiples. With the latest stock price at 9.20 CHF, the upside of Newron Pharmaceuticals SpA based on Relative Valuation is -266.7%.
The range of the Relative Valuation is (11.14) - (19.36) CHF.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.3x - 21.8x | 17.0x |
| Forward P/E multiples | 12.2x - 21.3x | 16.8x |
| Fair Price | (11.14) - (19.36) | (15.33) |
| Upside | -221.1% - -310.4% | -266.7% |
| Date | P/E |
| 2024-12-11 | -7.60 |
| 2024-12-10 | -7.59 |
| 2024-12-09 | -7.48 |
| 2024-12-06 | -7.48 |
| 2024-12-05 | -7.21 |
| 2024-12-04 | -7.33 |
| 2024-12-03 | -7.48 |
| 2024-12-02 | -7.70 |
| 2024-11-29 | -7.62 |
| 2024-11-28 | -7.48 |
| 2024-11-27 | -7.38 |
| 2024-11-26 | -6.98 |
| 2024-11-25 | -7.12 |
| 2024-11-22 | -7.08 |
| 2024-11-21 | -7.16 |
| 2024-11-20 | -6.89 |
| 2024-11-19 | -6.89 |
| 2024-11-18 | -6.92 |
| 2024-11-15 | -7.18 |
| 2024-11-14 | -7.49 |
| 2024-11-13 | -7.33 |
| 2024-11-12 | -7.26 |
| 2024-11-11 | -7.67 |
| 2024-11-08 | -7.77 |
| 2024-11-07 | -7.66 |
| 2024-11-06 | -7.60 |
| 2024-11-05 | -7.82 |
| 2024-11-04 | -7.87 |
| 2024-11-01 | -8.07 |
| 2024-10-31 | -7.90 |
| 2024-10-30 | -8.11 |
| 2024-10-29 | -8.15 |
| 2024-10-28 | -8.43 |
| 2024-10-25 | -8.56 |
| 2024-10-24 | -8.42 |
| 2024-10-23 | -8.68 |
| 2024-10-22 | -8.86 |
| 2024-10-21 | -8.82 |
| 2024-10-18 | -8.84 |
| 2024-10-17 | -7.76 |
| 2024-10-16 | -7.76 |
| 2024-10-15 | -8.01 |
| 2024-10-14 | -7.55 |
| 2024-10-11 | -7.25 |
| 2024-10-10 | -7.16 |
| 2024-10-09 | -7.23 |
| 2024-10-08 | -7.43 |
| 2024-10-07 | -7.48 |
| 2024-10-04 | -7.54 |
| 2024-10-03 | -7.77 |